# Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/  
OnCo record `paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Phase 2 or 3 results paper on Sacituzumab govitecan in Triple-negative breast cancer, in Journal of Clinical Oncology (2017), one of the most cited Europe PMC records with Sacituzumab govitecan in its title.

## Summary

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival. Results In 69 patients who received a median of five prior therapies (range, one to 12) since diagnosis, the confirmed objective response rate was 30% (partial response, n = 19; complete response, n = 2), the median response duration was 8.9 (95% CI, 6.1 to 11.3) months, and the clinical benefit rate (complete response + partial response + stable disease ≥ 6 months) was 46%. These responses occurred early, with a median onset of 1.9 months. Median progression-free survival was 6.0 (95% CI, 5.0 to 7.3) months, and median overall survival was 16.6 (95% CI, 11.1 to 20.6) months. Grade ≥ 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and diarrhea (13%); the incidence of febrile neutropenia was 7%. The majority of archival tumor specimens (88%) were moderately to strongly positive for Trop-2 by immunohistochemistry. No neutralizing antibodies to the ADC or antibody were detected, despite repeated cycles developed. Conclusion Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC. As a therapeutic target and predictive biomarker, Trop-2 warrants further research.

Indexed on Europe PMC as PubMed record 28291390 (DOI 10.1200/jco.2016.70.8297). Its title names Sacituzumab govitecan and its text names Triple-negative breast cancer; PubMed types it as a clinical trial report (Clinical Trial, Phase II, research-article, Clinical Trial, Phase I). It was matched automatically to the idea "TROP2 PET to choose and sequence TROP2 ADCs" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Journal of Clinical Oncology
- Year: 2017
- DOI: 10.1200/jco.2016.70.8297
- Authors: Bardia A, Mayer IA, Diamond JR, et al.
- What it means: One of the most cited trial reports Europe PMC returns for Sacituzumab govitecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Sacituzumab govitecan in the title and Triple-negative breast cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a phase 2 or 3 report by the record's publication type or its own wording, not by reading the paper.

## Sources

- J Clin Oncol 2017: https://doi.org/10.1200/jco.2016.70.8297
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28291390/
- Europe PMC: https://europepmc.org/article/MED/28291390

## Connected records

- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)
- ideas: [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/)

---
JSON: https://onco.cc/api/v1/entities/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017.json